Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Masimo Corporation (MASI - Analyst Report), a leader in non-invasive monitoring technology, recently revealed that Uludag University Hospital, a renowned healthcare and education institution in Turkey, has acquired Masimo SpHb, a novel expertise that permits medical practitioners to continuously and non-invasively track blood hemoglobin. 

Uludag University Hospital is one of only two hospitals in Turkey with accreditation from Joint Commission International. It is now using Masimo SpHb in its surgical rooms. The hospital has a total of 880 beds. Among other benefits, the hospital is gaining from lower sensor usage and better detection ability. 

Masimo is a market leader in the pulse oximetry monitoring equipment industry. Its prospects are encouraging, given the sizeable global market opportunity, adoption of pulse oximetry in non-critical areas of the hospital and growing barriers to entry due to additional non-invasive parameters.

While its patented SET offering remains its mainstay, the rainbow measurements represent another growth driver in hospital care. However, Masimo relies on third-party providers like original equipment manufacturers (OEMs) for a part of its business and customer concentration raises concern. Additionally, we remain concerned about its reliance on group purchasing organizations for the sale of its pulse oximetry products to hospitals in the domestic market.

Shipments have been growing at a steady rate fueled by new contracts. However, the renewal of the royalty agreement with Covidien plc (COV - Analyst Report) provides little or no benefit due to lower rates.

We also note Covidien’s effort to expand its oximetry and monitoring products portfolio. In late 2012, the company won Food and Drug Administration (FDA) 510(k) approval as well as European Economic Area (EEA) CE Mark clearance for its Nellcor Bedside Respiratory Patient Monitoring system.

Masimo carries a Zacks Rank #4 (Sell). Intuitive Surgical, Inc. (ISRG - Analyst Report) and HeartWare International Inc. (HTWR - Snapshot Report) are Zacks Rank #2 (Buy) stocks, which are expected to do well.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%